Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Chlorambucil
Drug ID BADD_D00429
Description A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Indications and Usage For treatment of chronic lymphatic (lymphocytic) leukemia, childhood minimal-change nephrotic syndrome, and malignant lymphomas including lymphosarcoma, giant follicular lymphoma, Hodgkin's disease, non-Hodgkin's lymphomas, and Waldenström’s Macroglobulinemia.
Marketing Status approved
ATC Code L01AA02
DrugBank ID DB00291
KEGG ID D00266
MeSH ID D002699
PubChem ID 2708
TTD Drug ID D0V8QT
NDC Product Code 69784-610; 49452-1911; 76055-0025; 80725-610; 50683-0384; 76388-635; 71052-212
UNII 18D0SL7309
Synonyms Chlorambucil | 4-(Bis(2-chloroethyl)amino)benzenebutanoic Acid | N,N-Di-(2-chloroethyl)-p-aminophenylbutyric Acid | Chloraminophene | Chlorbutin | NSC-3088 | NSC 3088 | NSC3088 | Leukeran | Lympholysin | Amboclorin | CB-1348 | CB 1348 | CB1348
Chemical Information
Molecular Formula C14H19Cl2NO2
CAS Registry Number 305-03-3
SMILES C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lymphopenia01.02.02.0020.000168%Not Available
Malaise08.01.01.0030.000392%
Mouth ulceration07.05.06.004--Not Available
Movement disorder17.01.02.010--Not Available
Mucosal inflammation08.01.06.002--Not Available
Muscle twitching15.05.03.005--Not Available
Myelodysplastic syndrome16.01.04.001; 01.10.04.001--
Myocardial infarction02.02.02.007; 24.04.04.0090.000280%
Myoclonus17.02.05.008--Not Available
Nausea07.01.07.0010.000448%
Neoplasm16.16.02.001--Not Available
Neoplasm malignant16.16.01.001--Not Available
Nephrotic syndrome20.05.01.002--
Neuralgia17.02.07.0050.000112%
Neuritis17.09.03.001--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Neutropenia01.02.03.0040.001231%Not Available
Oesophagitis07.08.05.0010.000112%
Oliguria20.01.03.0040.000112%Not Available
Optic atrophy06.09.02.001--Not Available
Overdose12.11.01.002--Not Available
Pain08.01.08.004--
Pancytopenia01.03.03.0030.000448%Not Available
Paraesthesia17.02.06.005; 23.03.03.0940.000168%
Paralysis17.01.04.004--Not Available
Paraparesis17.01.04.006--Not Available
Paresis17.01.04.008--Not Available
Peripheral motor neuropathy17.09.03.004--
Pleural effusion22.05.02.0020.000112%
Pneumonia22.07.01.003; 11.01.09.003--Not Available
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene